# Gilead Sciences operating income entity: /record/gilead-sciences.md predicate: operating_income page: /record/gilead-sciences/operating_income as_of: 2026-11-09 cite: AsOf. "Gilead Sciences quarterly operating income: 3,462,000,000 United States dollar", as of 2026-09-30. Claim clm_8490C244F9F5, https://asof.is/claim/clm_8490C244F9F5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm. As of November 9, 2026, the latest operating income figure on the AsOf record for Gilead Sciences is $3.46 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Gilead Sciences's latest full-year operating income is $10.02 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 19 claims on Gilead Sciences's operating income, 1 open and 18 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest operating income The newest figure for a shorter period, the quarter ended September 30, 2026: a quarterly_operating_income claim, kept apart from the full-year series. - [Gilead Sciences](/record/gilead-sciences.md) | quarterly_operating_income | 3,462,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_8490C244F9F5](/claim/clm_8490C244F9F5.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm ## Latest full-year operating income What the record asserts on 2026-11-09. - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 10,022,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_44AE227A69DA](/claim/clm_44AE227A69DA.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 2,164,507,000 United States dollar | valid 2007-12-31 to 2008-12-31 | conf 0.95 | superseded | superseded_by [clm_090DE766E964](/claim/clm_090DE766E964.md) | [clm_C1A5FF719A45](/claim/clm_C1A5FF719A45.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 2,678,541,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_C64800E0E7CB](/claim/clm_C64800E0E7CB.md) | [clm_090DE766E964](/claim/clm_090DE766E964.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 3,529,221,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_2C4E606A042E](/claim/clm_2C4E606A042E.md) | [clm_C64800E0E7CB](/claim/clm_C64800E0E7CB.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 3,962,222,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_BB578960787F](/claim/clm_BB578960787F.md) | [clm_2C4E606A042E](/claim/clm_2C4E606A042E.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 3,789,841,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_A7885EF38F91](/claim/clm_A7885EF38F91.md) | [clm_BB578960787F](/claim/clm_BB578960787F.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 4,010,175,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_BC08A5BEA713](/claim/clm_BC08A5BEA713.md) | [clm_A7885EF38F91](/claim/clm_A7885EF38F91.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 4,523,999,000 United States dollar | valid 2013-12-31 to 2014-12-31 | conf 0.95 | superseded | superseded_by [clm_830AD3CBC862](/claim/clm_830AD3CBC862.md) | [clm_BC08A5BEA713](/claim/clm_BC08A5BEA713.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 15,265,000,000 United States dollar | valid 2014-12-31 to 2015-12-31 | conf 0.95 | superseded | superseded_by [clm_3CA462AADF8A](/claim/clm_3CA462AADF8A.md) | [clm_830AD3CBC862](/claim/clm_830AD3CBC862.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 22,193,000,000 United States dollar | valid 2015-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_69A3F1EE9840](/claim/clm_69A3F1EE9840.md) | [clm_3CA462AADF8A](/claim/clm_3CA462AADF8A.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 17,633,000,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_757554EF6848](/claim/clm_757554EF6848.md) | [clm_69A3F1EE9840](/claim/clm_69A3F1EE9840.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 14,124,000,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_4AC1B328D986](/claim/clm_4AC1B328D986.md) | [clm_757554EF6848](/claim/clm_757554EF6848.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 8,200,000,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_023882052B6B](/claim/clm_023882052B6B.md) | [clm_4AC1B328D986](/claim/clm_4AC1B328D986.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 4,287,000,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_371075143050](/claim/clm_371075143050.md) | [clm_023882052B6B](/claim/clm_023882052B6B.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 4,071,000,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_C535F4EBB92C](/claim/clm_C535F4EBB92C.md) | [clm_371075143050](/claim/clm_371075143050.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 9,918,000,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_1850599904BE](/claim/clm_1850599904BE.md) | [clm_C535F4EBB92C](/claim/clm_C535F4EBB92C.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 7,330,000,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_4C71B25EAE57](/claim/clm_4C71B25EAE57.md) | [clm_1850599904BE](/claim/clm_1850599904BE.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 7,605,000,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_9D8D94D516C5](/claim/clm_9D8D94D516C5.md) | [clm_4C71B25EAE57](/claim/clm_4C71B25EAE57.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 1,662,000,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_44AE227A69DA](/claim/clm_44AE227A69DA.md) | [clm_9D8D94D516C5](/claim/clm_9D8D94D516C5.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | operating_income | 10,022,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_44AE227A69DA](/claim/clm_44AE227A69DA.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm ## What replaced what - $2.16 billion (2007-12-31 to 2008-12-31, [clm_C1A5FF719A45](/claim/clm_C1A5FF719A45.md)) was replaced by $2.68 billion from 2008-12-31 ([clm_090DE766E964](/claim/clm_090DE766E964.md)) - $2.68 billion (2008-12-31 to 2009-12-31, [clm_090DE766E964](/claim/clm_090DE766E964.md)) was replaced by $3.53 billion from 2009-12-31 ([clm_C64800E0E7CB](/claim/clm_C64800E0E7CB.md)) - $3.53 billion (2009-12-31 to 2010-12-31, [clm_C64800E0E7CB](/claim/clm_C64800E0E7CB.md)) was replaced by $3.96 billion from 2010-12-31 ([clm_2C4E606A042E](/claim/clm_2C4E606A042E.md)) - $3.96 billion (2010-12-31 to 2011-12-31, [clm_2C4E606A042E](/claim/clm_2C4E606A042E.md)) was replaced by $3.79 billion from 2011-12-31 ([clm_BB578960787F](/claim/clm_BB578960787F.md)) - $3.79 billion (2011-12-31 to 2012-12-31, [clm_BB578960787F](/claim/clm_BB578960787F.md)) was replaced by $4.01 billion from 2012-12-31 ([clm_A7885EF38F91](/claim/clm_A7885EF38F91.md)) - $4.01 billion (2012-12-31 to 2013-12-31, [clm_A7885EF38F91](/claim/clm_A7885EF38F91.md)) was replaced by $4.52 billion from 2013-12-31 ([clm_BC08A5BEA713](/claim/clm_BC08A5BEA713.md)) - $4.52 billion (2013-12-31 to 2014-12-31, [clm_BC08A5BEA713](/claim/clm_BC08A5BEA713.md)) was replaced by $15.27 billion from 2014-12-31 ([clm_830AD3CBC862](/claim/clm_830AD3CBC862.md)) - $15.27 billion (2014-12-31 to 2015-12-31, [clm_830AD3CBC862](/claim/clm_830AD3CBC862.md)) was replaced by $22.19 billion from 2015-12-31 ([clm_3CA462AADF8A](/claim/clm_3CA462AADF8A.md)) - $22.19 billion (2015-12-31 to 2016-12-31, [clm_3CA462AADF8A](/claim/clm_3CA462AADF8A.md)) was replaced by $17.63 billion from 2016-12-31 ([clm_69A3F1EE9840](/claim/clm_69A3F1EE9840.md)) - $17.63 billion (2016-12-31 to 2017-12-31, [clm_69A3F1EE9840](/claim/clm_69A3F1EE9840.md)) was replaced by $14.12 billion from 2017-12-31 ([clm_757554EF6848](/claim/clm_757554EF6848.md)) - $14.12 billion (2017-12-31 to 2018-12-31, [clm_757554EF6848](/claim/clm_757554EF6848.md)) was replaced by $8.2 billion from 2018-12-31 ([clm_4AC1B328D986](/claim/clm_4AC1B328D986.md)) - $8.2 billion (2018-12-31 to 2019-12-31, [clm_4AC1B328D986](/claim/clm_4AC1B328D986.md)) was replaced by $4.29 billion from 2019-12-31 ([clm_023882052B6B](/claim/clm_023882052B6B.md)) - $4.29 billion (2019-12-31 to 2020-12-31, [clm_023882052B6B](/claim/clm_023882052B6B.md)) was replaced by $4.07 billion from 2020-12-31 ([clm_371075143050](/claim/clm_371075143050.md)) - $4.07 billion (2020-12-31 to 2021-12-31, [clm_371075143050](/claim/clm_371075143050.md)) was replaced by $9.92 billion from 2021-12-31 ([clm_C535F4EBB92C](/claim/clm_C535F4EBB92C.md)) - $9.92 billion (2021-12-31 to 2022-12-31, [clm_C535F4EBB92C](/claim/clm_C535F4EBB92C.md)) was replaced by $7.33 billion from 2022-12-31 ([clm_1850599904BE](/claim/clm_1850599904BE.md)) - $7.33 billion (2022-12-31 to 2023-12-31, [clm_1850599904BE](/claim/clm_1850599904BE.md)) was replaced by $7.61 billion from 2023-12-31 ([clm_4C71B25EAE57](/claim/clm_4C71B25EAE57.md)) - $7.61 billion (2023-12-31 to 2024-12-31, [clm_4C71B25EAE57](/claim/clm_4C71B25EAE57.md)) was replaced by $1.66 billion from 2024-12-31 ([clm_9D8D94D516C5](/claim/clm_9D8D94D516C5.md)) - $1.66 billion (2024-12-31 to 2025-12-31, [clm_9D8D94D516C5](/claim/clm_9D8D94D516C5.md)) was replaced by $10.02 billion from 2025-12-31 ([clm_44AE227A69DA](/claim/clm_44AE227A69DA.md)) ## Questions this record answers ### What is Gilead Sciences's current operating income? The latest figure on the record is $3.46 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $10.02 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 9, 2026. ### What was Gilead Sciences's operating income for the quarter ended September 30, 2026? $3.46 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Gilead Sciences's operating income last change? The latest value on the record is $10.02 billion, dated December 31, 2025; before it the record holds $1.66 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Gilead Sciences's operating income before $10.02 billion? $1.66 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/gilead-sciences/operating_income (markdown: /record/gilead-sciences/operating_income.md) - Entity twin: /record/gilead-sciences.md ยท timeline: /timelines/gilead-sciences.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.